Table 1 Anti-GPCR antibodies under clinical trials
From: Engineering therapeutic antibodies targeting G-protein–coupled receptors
Receptor target | Antibody drug | Disease indication | Company/institute | Status |
CCR2 | MNL1202 | Bone metastases | Southwest Oncology group | Phase II |
Arterial inflammation | Takeda | Phase II | ||
Atherosclerosis | Millennium Pharmaceuticals | Phase II | ||
CCR4 | KW-0761 (Mogamulizumab) | Adult T-cell leukemia and lymphoma | Kyowa Hakko Kirin | Phase II |
Peripheral T/NK-cell lymphoma | Kyowa Hakko Kirin | Phase II | ||
Adult PTCL | Kyowa Hakko Kirin | Phase II | ||
CTCL | Kyowa Hakko Kirin | Phase III | ||
AMG761 | Asthma | Amgen | Phase I | |
CCR5 | PRO140 | HIV infection | CytoDyn | Phase III |
CCR5 mAb004 | HIV infection | Human Genome Science | Phase I | |
HGS1025 | Ulcerative colitis | Human Genome Science | Phase I | |
HGS004 | HIV infection | Human Genome Science | Phase I | |
CCR9 | MLN3126 | Inflammation | Takeda | Phase I |
CXCR4 | BMS-936564 | Multiple myeloma | Bristol-Myers Squibb | Phase I |
ALX-0651 | Stem cell mobilization | Ablynx | Phase I | |
LY-2624587 | Metastatic cancer | Eli Lilly | Phase I | |
CXCR5 | SAR113244 | Systemic lupus erythematosus | Sanofi | Phase I |
C5aR | NNC0151-0000-0000 (NN-8209) | Rheumatoid arthritis | Novo Nordisk | Phase II |
NNC0215-0384 (NN-8210) | Rheumatoid arthritis, inflammation | Novo Nordisk | Phase I | |
CGRP-R | AMG-334 | Migraine | Amgen | Phase II |
Hot flashes | Amgen | Phase I | ||
GCG-R | AMG-477 | Type 2 diabetes | Amgen | Phase I |
FZD1, 2, 5, 7, 8 | OMP-18R5 (Vantictumab) | Solid tumor (NSCLC) | Oncomed | Phase I (combined with Docetaxel) |
Metastatic breast cancer | Oncomed | Phase I (combined with paclitaxel) |
